

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 20-965

PHARMACOLOGY REVIEW(S)

REVIEW AND EVALUATION OF PHARMACOLOGY/TOXICOLOGY DATA:

KEY WORDS: 5-aminolevulinic acid, ALA, photodynamic therapy, actinic keratoses
Reviewer Name: Amy Nostrandt
Division Name: Division of Dermatologic and Dental Drug Products
HFD# 540
Review Completion Date: 11/19/1999

NOV 19 1999

Review number: 2
IND/NDA number: NDA 20-965
Serial number/date/type of submission: resubmission (AZ), response to AE letter, received 10/4/1999


Information to sponsor: Yes () No (X)
Sponsor (or agent): Guidelines, Inc. for DUSA Pharmaceuticals, Inc.
Manufacturer for drug substance: [redacted]

Drug:

Code Name: 5-ALA HCl, 5-ALA, ALA
Generic Name: 5-aminolevulinic acid HCl
Trade Name: Levulan® (aminolevulinic acid HCl) Kerastick™ for topical solution 20%

Chemical Name: 5-amino-4-oxopentanoic acid
CAS Registry Number: not included in this submission
Molecular Formula/ Molecular Weight/Structure:

(5-aminolevulinate)
C₅H₉NO₃, MW = 131.13



Relevant INDs/NDAs/DMFs:

in HFD-150:

IND [redacted]

IND [redacted]

IND [redacted]

IND [redacted]

[redacted]

in HFD-540:

IND [redacted]

IND [redacted]

IND [redacted]

IND [redacted]

IND [redacted]

IND [redacted]

for topical photodynamic therapy of actinic keratosis

[redacted]

in HFD-580:

IND [redacted]
IND [redacted]

Drug Class: photodynamic therapy

Indication: for the treatment of [redacted] actinic keratoses of the face and scalp

Clinical formulation: constituted Levulan® (5-ALA HCl)

Ingredient	"theoretical quantity" mg/ml
Levulan (5-ALA HCl)	[redacted]
Alcohol, USP	
Purified water, USP	
Laureth-4	
Isopropyl alcohol, USP	
Polyethylene glycol	
[redacted]	
Total	

Route of administration: An ampoule containing 5-ALA HCl in powder form is broken to allow admixture with the vehicle to form a 20% solution. The solution is immediately applied topically to the lesion only. After [redacted] hours, the site is irradiated with the applicant's companion device, a blue light source with an emission peak of 417 nm and a bandwidth of [redacted] nm.

Introduction and drug history: The current submission is a resubmission of an approvable NDA. The only changes that impact pharmacology and toxicology are in the label. Those changes are addressed below.

OVERALL SUMMARY AND EVALUATION:

Communication Review:

- Labeling Review (NDA):

- Under "Carcinogenesis, Mutagenesis, Impairment of Fertility," all references to "5-ALA" were changed to read [redacted] by the applicant. References to the drug substance, as opposed to the drug product, were changed to ALA HCl, as proposed by the chemistry reviewer. For descriptions of genotoxicity studies, which were conducted using a solution of 5-ALA in an acetate buffer, the wording should be changed back to read ALA.
- The sentence, "PpIX formation was not demonstrated in the in vitro studies" should be moved to a position immediately after the descriptions of those studies and "the" should be changed to "these."
- Other minor changes, such as more concise wording, case corrections, etc., are made below.

RECOMMENDATIONS:

The following sections should be revised as follows:

Carcinogenesis, Mutagenesis, Impairment to Fertility: No carcinogenicity testing has been carried out using [redacted] ALA. No evidence of mutagenic effects was seen in four studies conducted with ALA to evaluate this potential. In the *Salmonella-Escherichia coli* mammalian microsome reverse mutation assay (Ames mutagenicity assay), no increases in the number of revertants were observed with any of the tester strains. In the *Salmonella-Escherichia coli* mammalian microsome reverse mutation assay in the presence of solar light radiation (Ames mutagenicity assay with light), [redacted] ALA did not cause an increase in the number of revertants per plate of any of the tester strains in the presence [redacted] or [redacted] absence of [redacted] simulated solar light. In the L5178Y TK⁺ mouse lymphoma forward mutation assay, [redacted] ALA was evaluated as negative with and without metabolic activation under the study conditions. PpIX formation was not demonstrated in any of these *in vitro* studies. In the *in vivo* mouse micronucleus assay, [redacted] ALA was considered negative under the study exposure conditions. In contrast, at least one report in the literature has noted genotoxic effects in cultured rat hepatocytes after ALA exposure with PpIX formation. Other studies have documented oxidative DNA damage *in vivo* and *in vitro* as a result of ALA exposure.

No assessment of effects of [redacted] ALA HCl on fertility has been performed in laboratory animals. It is unknown what effects systemic exposure to [redacted] ALA HCl might have on fertility or reproductive function.

Pregnancy Category C: Animal reproduction studies have not been conducted with [redacted] ALA HCl. It is also not known whether LEVULAN KERASTICK Topical Solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. LEVULAN KERASTICK Topical Solution should be given to a pregnant woman only if clearly needed.

Nursing Mothers: The levels of ALA or its metabolites in the milk of subjects treated with LEVULAN KERASTICK Topical Solution have not been measured [redacted]. Because many drugs are excreted in human milk, caution should be exercised when LEVULAN KERASTICK Topical Solution is administered to a nursing woman.

APPEARS THIS WAY
ON ORIGINAL

[redacted] /S/ 11/19/99
Amy C. Nostrandt, D.V.M., Ph.D.
Pharmacologist/Toxicologist

cc:

NDA 20-965

HFD-340

HFD-540

HFD-540/PHARM/Nostrandt

HFD-540/TLPHARM/Jacobs

HFD-540/MO/Okun

HFD-540/CHEM/Hathaway

HFD-540/PMS/Cintron

C:\word files\nda\20965rel.doc

Draft date (# of drafts): 11/19/99 (1)

Concurrence Only:

HFD-540/DD/WILKIN

S 11/21/99

HFD-540/TLPHARM/JACOBS

YFS
11/19/99
fn
12-3

APPEARS THIS WAY
ON ORIGINAL

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.